A detailed history of Srs Capital Advisors, Inc. transactions in Alkermes Plc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 1,125 shares of ALKS stock, worth $31,162. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,125
Previous 1,089 3.31%
Holding current value
$31,162
Previous $26,000 19.23%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$23.01 - $28.55 $828 - $1,027
36 Added 3.31%
1,125 $31,000
Q2 2024

Aug 06, 2024

BUY
$23.21 - $27.24 $25,275 - $29,664
1,089 New
1,089 $26,000
Q2 2018

Aug 21, 2018

SELL
$40.56 - $51.36 $973 - $1,232
-24 Closed
0 $0
Q1 2018

May 14, 2018

BUY
$53.61 - $67.26 $1,286 - $1,614
24 New
24 $1,000
Q4 2017

Feb 15, 2018

SELL
$47.69 - $55.39 $9,394 - $10,911
-197 Closed
0 $0
Q3 2017

Nov 15, 2017

BUY
$49.16 - $54.45 $9,684 - $10,726
197
197 $10,000

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.55B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Srs Capital Advisors, Inc. Portfolio

Follow Srs Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Srs Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Srs Capital Advisors, Inc. with notifications on news.